RAS MUTATION
Clinical trials for RAS MUTATION explained in plain language.
Never miss a new study
Get alerted when new RAS MUTATION trials appear
Sign up with your email to follow new studies for RAS MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug RSC-1255 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: RasCal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill targets Hard-to-Treat cancers with RAS gene flaw
Disease control Recruiting nowThis early-phase study tests an experimental pill, AN9025, in adults with advanced solid tumors that have a specific genetic change called a RAS mutation. The main goal is to find a safe dose and check for side effects. About 118 participants will take the drug daily or weekly an…
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for hard-to-treat cancers: targeted combo trial opens
Disease control Recruiting nowThis study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …
Matched conditions: RAS MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New MEK inhibitor PAS-004 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called PAS-004 in people with advanced solid tumors that have certain gene mutations (RAS, NF1, or RAF). The main goal is to see how safe the drug is and what side effects it causes. About 48 participants will take the drug by mouth da…
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: liquid biopsy guides smarter drug choice
Disease control Recruiting nowThis study looks at people with advanced colorectal cancer whose tumor tissue shows no RAS/BRAF mutation, but a liquid biopsy (blood test) finds a RAS mutation. It compares two standard drug combos (FOLFIRI plus either cetuximab or bevacizumab) to see which works better at stoppi…
Matched conditions: RAS MUTATION
Phase: PHASE3 • Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Massive study aims to unlock secrets of rare genetic disorders
Knowledge-focused Recruiting nowThis study is collecting blood, tissue, and medical information from up to 1,000 people with RASopathies—a group of genetic conditions that affect development and raise cancer risk. Researchers will store these samples and data in a database for future studies. The goal is to lea…
Matched conditions: RAS MUTATION
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC